![Joanne Yeakley](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profilo
Joanne Yeakley is the founder of BioSypder Technologies, Inc. where she holds the title of Vice President-Research & Development starting in 2011.
Posizioni attive di Joanne Yeakley
Società | Posizione | Inizio |
---|---|---|
BioSypder Technologies, Inc.
![]() BioSypder Technologies, Inc. Medical SpecialtiesHealth Technology BioSpyder Technologies, Inc. is a biotechnology company based in Carlsbad, CA. BioSpyder Technologies has developed a novel product for targeted sequencing called Tempo-Seq, which is a gene expression profiling tool designed to monitor hundreds to thousands of genes at once in high throughput. Tempo-Seq can analyze expression in samples with thousands of cells or from single cells without pre-amplification, maximizing utilization of precious or limited samples. The assay content is flexible and customizable, delivering unprecedented accuracy and sensitivity with simplified data analysis that eliminates the need for bioinformatics. Tempo-Seq assays deliver an easy-to-use solution for customers doing expression profiling for any species. The private company was founded in 2011 by Joel McComb, Bruce Seligmann, and Joanne Yeakley, with Joel McComb serving as the CEO since then. | Fondatore | 01/12/2011 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
BioSypder Technologies, Inc.
![]() BioSypder Technologies, Inc. Medical SpecialtiesHealth Technology BioSpyder Technologies, Inc. is a biotechnology company based in Carlsbad, CA. BioSpyder Technologies has developed a novel product for targeted sequencing called Tempo-Seq, which is a gene expression profiling tool designed to monitor hundreds to thousands of genes at once in high throughput. Tempo-Seq can analyze expression in samples with thousands of cells or from single cells without pre-amplification, maximizing utilization of precious or limited samples. The assay content is flexible and customizable, delivering unprecedented accuracy and sensitivity with simplified data analysis that eliminates the need for bioinformatics. Tempo-Seq assays deliver an easy-to-use solution for customers doing expression profiling for any species. The private company was founded in 2011 by Joel McComb, Bruce Seligmann, and Joanne Yeakley, with Joel McComb serving as the CEO since then. | Health Technology |
- Borsa valori
- Insiders
- Joanne Yeakley